 Today we have Steve Saviet from Valeo Pharma. How are you today, Steve? Very good, Tracy, and great to be back on Investor Talk. I have to tell you, I really missed out on this webcast that you had on Tuesday. I heard it was outstanding. It was great. In fact, many people thought it was our best ever. I think we kept it concise. Today, when I say today, not physically today, but just today and this time, what's nice is we can talk more numbers. I think that's what investors want to hear. Before, we couldn't talk numbers because we really didn't have the numbers to talk about. All we could talk about was the benefits of our drugs. They're still clearly there, but I think investors like to say, yes, okay, I understand, great drug, but what is it doing? How is it changing your balance sheet and your income statement? I think we finally can talk about that. I think people gravitate to that more so than just knowing about how this affects your asthma or things of that nature. I think it's positive that we can actually relate more to the retail investor. Steve, I tell you, you've had a lot of news recently, phenomenal news. In addition to incredible Q4 results, your record Q4 results, outstanding 2022 results, 22 results, up over 105%. You've also announced a new treatment of hospitalized COVID-19 patients, which it's my understanding, increased the survival rate by 51%. Did I read that right? That's correct. This drug was developed by a U.S. company called Veru. It's called the chemical name is sabizabulin. It's an antiviral anti-inflammatory. It has gone through one phase three clinical trial, which showed those quite significant results of reduction of deaths by over 50%. It has been filed recently with Health Canada. We have to go through the Health Canada process, which can take time up to a year. We'll see how quickly the Health Canada responds to the application, but we're very encouraged. This is really a backdrop to everything that Valeo does as we look for innovative medicines that really bring value to Canadians. I think sabizabulin certainly checks the boxes there for people that have advanced respiratory distress and are in our hospitalized with COVID-19. I'll tell you, Steve, this really touched my heart. I think all of us have lost someone during COVID-19. Say one of us end up in the hospital for COVID-19. Do we ask for this or how do we get access to this treatment? Well, first off, it's not currently approved in Canada. We have to go through the Health Canada process. That's a necessary process to ensure that the drug complies with our Canadian guidelines. When the product gets approved, it'll be put into the hospital protocols for patients that, as I mentioned earlier, are under some kind of respiratory distress. It'll be up to the various protocols to determine at what time in your illness that you should have sabizabulin administered. It comes in a capsule and it's generally only for hospitalized patients. This is not something you would be taking at home. Again, it's for patients that are clearly in some type of respiratory distress. The results and it has a specific mode of action, which is quite interesting. As I mentioned, the results are quite outstanding in terms of the reduction against standard of care. We were comparing the drug to what you're getting in the hospital today. To see this significant reduction in fatalities and death is quite amazing. I think you'll be hearing more about sabizabulin in the weeks and months to come. Can you tell me how you managed to get this? It seems like it was fast tracked because it sounds like I'm not familiar with this particular treatment before. You're already filing it with Health Canada. You've already done the placebo test and received those results. Can you tell me how you've managed to do this? Is it because of your excellent financial results last quarter? Steve, what has allowed you to fast track this, please? The drug, as I mentioned, was developed by a biotech company at the U.S. called Veru, a very interesting company, very advanced scientifically. They performed the clinical trials and through various business development activities that we continuously undertake, we were able to enter into discussions with Veru. Yes, we'd like to fast track this drug into Canada, but it has to go through a process which takes time. The results are, as I mentioned, are truly outstanding when you look at the effectiveness. This touches all these patients very dramatically. I think the death reduction is one of every five people treated, which is a huge number of patients. It gives, I believe, a significant new advancement in treating these very ill COVID patients. Well, Steve, as always, it's a pleasure to get updates from you and all of the exciting things that Vallejo is currently doing. You actually have six other products which are really leading the charge for revenue for the company right now. In addition to expanding your portfolio, you have six products and treatments that are actually bringing in revenue and taking care of all of us. That's correct. In total, we now commercialized 12 drugs, six of which are undergoing some significant revenue growth and are truly innovative in their various and respective areas, whether it be asthma, whether it be ophthalmology, whether it be in the hospital for treating blood clots or trying to prevent blood clots. It's nice. It's diversified portfolio. It has growth. I think your viewers can look forward to more news as Vallejo continues to try to add to these products and leverage. When I say leverage, our commercial infrastructure, leverage means adding products, adding revenue without adding cost or meaningful cost, significant cost. I think that's where we finally have got our company. Looking forward to being able to talk about new therapies, but certainly not taking anything away from the huge growth. I'll single out one. Enter's there as I've called it our diamond. It truly is a very first-in-class type of therapy. Inhale, asthma therapy. We believe it is growing quite quickly. I'll make one comment about our asthma. We talked about the first quarter a little bit, but our asthma therapies in Q1 compared to Q4, revenue grew 40% in that one quarter. That's a dramatic. We expect that type of growth to continue for years to come. Very exciting times at Vallejo, but as we mentioned off-air, it takes a lot of people. It's a lot of moving parts to run a company with logistics and activities, whether it be medical, regulatory, obviously sales and commercial. It's all the wonderful people in Vallejo that make that happen. For those of you out there who are layoffs, farmers, shareholders, you got to be pleased. Steve, thank you so much for joining us today. Tracy, wonderful. I look forward to being back in your future with some other good news.